N-[3-[[[(Cyanoamino)phenoxymethylene]amino]methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]urea | 441756-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[3-[[[(Cyanoamino)phenoxymethylene]amino]methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]urea
• 英文别名: phenyl N-cyano-N'-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamimidate
• CAS: 441756-43-0
• 化学式: C₂₆H₂₂N₆O₄
• 分子量: 482.498
• InChiKey: ZLXCXYYKOIUGCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Amino-substituted compounds useful as inhibitors of impdh enzyme
  申请人：——

  公开号：US20020183315A1

  公开（公告）日：2002-12-05

  The present invention discloses compounds useful in treating or preventing IMPDH-associated disorders, such as transplant rejection and autoimmune diseases, having the formula (I), 1 wherein X is —C(O)—, —C(S)—, or —S(O) 2 —; A is an optionally-substituted saturated or unsaturated monocyclic or bicyclic ring; B is a saturated or unsaturated monocyclic or bicyclic ring system having at least one substituent Q which is selected from R 7 and R 8 ; R 7 is selected from (C 0 -C 6 )alkyl, (C 2 -C 6 )alkenyl and (C 2 -C 6 )alkynyl and R 7 is substituted with 2 R 8 is selected from (C 0 -C 6 )alkyl, (C 2 -C 6 )alkenyl and (C 2 C 6 )alkynyl and R 8 is substituted with 3 and Z 1 through Z 5 are as defined in the specification.

  本发明揭示了一种化合物，其具有公式（I），可用于治疗或预防与IMPDH相关的疾病，如移植排斥和自身免疫性疾病，其中X为—C（O）—，—C（S）—或—S（O）2—; A为可选择取代的饱和或不饱和单环或双环环；B是具有至少一个取代基Q的饱和或不饱和单环或双环环系统，所述取代基Q选择自R7和R8；R7选择自（C0-C6）烷基，（C2-C6）烯基和（C2-C6）炔基，且R7被取代；R8选择自（C0-C6）烷基，（C2-C6）烯基和（C2C6）炔基，且R8被取代，且Z1至Z5如规范中所定义。
• Angiogenesis inhibitors
  申请人：THE JOHNS-HOPKINS UNIVERSITY

  公开号：EP2803357A2

  公开（公告）日：2014-11-19

  Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.

  本文描述了抑制血管生成和治疗或预防与血管生成有关的疾病或紊乱（或其症状）的方法，其中向受试者施用抗血管生成化合物。
• [EN] METABOLISM-MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DU MÉTABOLISME ET UTILISATIONS ASSOCIÉES
  申请人：UNIV QUEENSLAND

  公开号：WO2006017896A1

  公开（公告）日：2006-02-23

  The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5' monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.

  本发明旨在提供调节脂肪生成的方法和试剂。更具体地，本发明涉及能够调节次黄嘌呤-5'一磷酸脱氢酶（IMPDH）的水平或功能活性的分子，以及它们在调节脂肪细胞中脂质的积累和/或脂肪细胞前体分化为脂肪细胞方面的作用，从而用于治疗或预防与脂肪量相关的疾病，包括但不限于肥胖症、脂肪瘤、脂肪瘤病、恶病质或脂肪营养不良，或由于创伤或萎缩性条件导致的脂肪组织损失。
• METABOLISM-MODULATING AGENTS AND USES THEREFOR
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：EP1786415A1

  公开（公告）日：2007-05-23
• Metabolism-modulating agents and uses therefor
  申请人：Whitehead Paul Jonathan

  公开号：US20060106097A1

  公开（公告）日：2006-05-18

  The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5′ monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.